ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) – Investment analysts at HC Wainwright lowered their Q2 2025 earnings per share estimates for ORIC Pharmaceuticals in a research report issued to clients and investors on Monday, January 13th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.55) per share for the quarter, down from their previous forecast of ($0.54). HC Wainwright currently has a “Buy” rating and a $21.00 price objective on the stock. The consensus estimate for ORIC Pharmaceuticals’ current full-year earnings is ($1.84) per share. HC Wainwright also issued estimates for ORIC Pharmaceuticals’ Q3 2025 earnings at ($0.57) EPS.
ORIC Pharmaceuticals (NASDAQ:ORIC – Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.01).
Check Out Our Latest Research Report on ORIC Pharmaceuticals
ORIC Pharmaceuticals Trading Down 4.6 %
Shares of ORIC stock opened at $9.58 on Thursday. The firm’s 50 day moving average is $9.00 and its 200 day moving average is $9.48. The stock has a market capitalization of $676.03 million, a P/E ratio of -5.32 and a beta of 1.18. ORIC Pharmaceuticals has a 12 month low of $6.33 and a 12 month high of $16.65.
Insiders Place Their Bets
In related news, CFO Dominic Piscitelli sold 8,851 shares of the company’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $8.28, for a total value of $73,286.28. Following the completion of the transaction, the chief financial officer now directly owns 106,764 shares in the company, valued at approximately $884,005.92. The trade was a 7.66 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Pratik S. Multani sold 8,850 shares of the stock in a transaction on Monday, December 16th. The shares were sold at an average price of $8.28, for a total value of $73,278.00. Following the completion of the transaction, the insider now directly owns 46,765 shares in the company, valued at approximately $387,214.20. This represents a 15.91 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,361 shares of company stock worth $350,749 in the last ninety days. 5.55% of the stock is currently owned by insiders.
Hedge Funds Weigh In On ORIC Pharmaceuticals
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp raised its holdings in shares of ORIC Pharmaceuticals by 62.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 186,484 shares of the company’s stock valued at $1,318,000 after buying an additional 71,394 shares in the last quarter. Rhumbline Advisers raised its stake in shares of ORIC Pharmaceuticals by 53.7% during the second quarter. Rhumbline Advisers now owns 92,702 shares of the company’s stock worth $655,000 after acquiring an additional 32,402 shares in the last quarter. Victory Capital Management Inc. lifted its holdings in shares of ORIC Pharmaceuticals by 8.3% in the 2nd quarter. Victory Capital Management Inc. now owns 95,850 shares of the company’s stock worth $678,000 after acquiring an additional 7,310 shares during the last quarter. Quest Partners LLC lifted its holdings in shares of ORIC Pharmaceuticals by 253.2% in the 2nd quarter. Quest Partners LLC now owns 10,378 shares of the company’s stock worth $73,000 after acquiring an additional 7,440 shares during the last quarter. Finally, American Century Companies Inc. boosted its stake in shares of ORIC Pharmaceuticals by 15.1% in the 2nd quarter. American Century Companies Inc. now owns 84,201 shares of the company’s stock valued at $595,000 after purchasing an additional 11,034 shares in the last quarter. 95.05% of the stock is currently owned by hedge funds and other institutional investors.
About ORIC Pharmaceuticals
ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.
Featured Articles
- Five stocks we like better than ORIC Pharmaceuticals
- Insider Trades May Not Tell You What You Think
- AI Demand Sparks Opportunities for These 3 Nuclear Energy Leaders
- How to Invest in the FAANG Stocks
- TSMC: Long-Term Outlook Still Strong as Geopolitical Risk Rises
- Are Penny Stocks a Good Fit for Your Portfolio?
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
Receive News & Ratings for ORIC Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ORIC Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.